AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2025-04-27
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized,
parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in
participants with open-angle glaucoma or ocular hypertension